ABOUT US

We are Changing the Drug Discovery Paradigm

Congruence Therapeutics is a drug discovery company harnessing the power of innovative fields such as protein dynamics, biophysics, machine learning and computational chemistry.

Leadership

We have a uniquely qualified team, founded by serial life sciences entrepreneur Clarissa Desjardins, PhD, most recently the founder and CEO of rare disease company Clementia Pharmaceuticals (Nasdaq: CMTA) sold to Ipsen for US$1.31 billion in 2019.  Learn more about our outstanding team below.

Clarissa Desjardins,
Ph.D.
Chief Executive Officer
Charles Grubsztajn,
BCL, MBA
Chief Operating Officer
Sharath Hegde,
Ph.D.
Chief Scientific Officer
Michael D. Harvey, Ph.D.
Chief Development Officer
Frank Taffy, JD
Chief Business Officer
Edith Bellavance, M.Sc.
Executive Director, DMPK
Alex Caron, M.Sc.
Executive Director, Pharmacology
Maximilian Ebert,
Ph.D.
Executive Director, Computational Molecular Sciences
Lee D. Fader,
Ph.D.
Vice President Chemistry
Michael Rock Goldsmith, Ph.D.
Chief Innovation Scientist
Jean-François Marquis,
Ph.D.
Vice President Discovery Research
Myriam Taillefer,
CPA
Vice President of Finance

Board of Directors & Observers

Nancy Harrison
Daniel Hétu
Nathaniel David
David Bonita
Didier Leconte
Alex Munns
Investors

In March 2023, we announced the close of an extension to our Series A financing, bringing the total amount raised to over US$65 million. This extension was led by new investor BDC Capital’s Thrive Venture Fund, with participation from current investors Amplitude Ventures, Fonds de solidarité FTQ, OrbiMed, Investissement Quebec (IQ), SilverArc, and others.

In December 2021, we completed a Series A financing of US$50 million with top U.S. and Canadian investors, including OrbiMed, Amplitude Ventures, and Driehaus.